Hypothesis: Physiological, low‑level pain signals—particularly those conveyed by CGRP and substance P—actively recruit and activate immune cells that eliminate senescent cells, thereby contributing to tissue homeostasis and longevity. Chronic analgesic use (opioids, NSAIDs, or CGRP antagonists) dampens this neuro‑immune communication, leading to accelerated accumulation of senescent cells and premature aging, independent of the drugs’ direct toxicities.

Mechanistic rationale: CGRP released from sensory neurons can polarize macrophages toward an M2‑like phagocytic state that enhances clearance of apoptotic and senescent cells substance P and CGRP do amplify age-related neuroinflammation. Substance P stimulates neutrophil extracellular trap (NET) formation and ROS production, which have senolytic activity in vitro. In aging, declining sensory neuron function reduces these neuropeptide tones, while pharmacological blockade (e.g., morphine‑induced µ‑opioid receptor activation inhibits CGRP release; NSAIDs suppress prostaglandin‑mediated sensitization that amplifies neuropeptide signaling) further diminishes the signal. Consequently, immune surveillance of senescent cells wanes, allowing p16Ink4a+ cells to persist and secrete SASP factors that drive inflammation and tissue dysfunction.

Testable predictions:

1. In aged mice, chronic low‑dose morphine treatment will increase hepatic and renal p16Ink4a+ cell burden compared with saline controls, despite equivalent exposure to a senolytic agent (e.g., navitoclax).
2. Pharmacological blockade of the CGRP receptor (using olcegepant) will recapitulate the morphine effect, whereas CGRP agonist administration will reduce senescent cell load even in the presence of morphine.
3. Adoptive transfer of macrophages from morphine‑treated mice into senescent‑cell‑laden recipients will show reduced phagocytic capacity versus macrophages from untreated mice.
4. Longitudinal biomarker analysis in humans on chronic opioid therapy will reveal higher circulating senescent‑cell‑associated cfDNA and SASP cytokines (IL-6, TNF‑α) after adjusting for pain severity and comorbidities.

Falsifiability: If chronic analgesic exposure does not alter senescent cell accumulation or immune‑cell senescence‑clearance metrics in the above models, the hypothesis is refuted. Conversely, demonstration that restoring CGRP/substance P signaling rescues senescent cell clearance despite ongoing analgesia would support the proposed neuro‑immune longevity pathway.